Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Acute Effects of Functional Inspiratory Muscle Training in Elite Male Volleyball Players

NCT07763002 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-05-01
Last updated
2026-08-13

Condition(s) studied

Athletic Performance

Investigational drug(s) / intervention(s)

Functional Inspiratory Muscle Training With POWERbreathe

Functional Inspiratory Muscle Training With POWERbreathe: A POWERbreathe pressure-threshold inspiratory muscle training device is used during a sport-specific fixed-ball throwing drill after warm-up. Before training, maximal inspiratory pressure is measured using a mouth pressure meter. The device resistance is individualized at 50% of maximal inspiratory pressure. Participants complete two sets of 30 resisted inspirations, totaling 60 breaths, over approximately 10 to 12 minutes. Expiration is unrestricted. The intervention is delivered once.

Study summary

This randomized controlled trial evaluates the acute effects of a single session of functional inspiratory muscle training on muscle oxygenation, exercise capacity, dynamic balance, and agility in elite male volleyball players aged 18 to 25 years. Thirty participants will be randomly assigned in a 1:1 ratio to an intervention group or a no-intervention control group. The intervention group will perform 60 resisted breaths at 50% of maximal inspiratory pressure using a POWERbreathe device during a sport-specific fixed-ball throwing drill. Both groups will complete assessments before and immediately after the intervention period on the same day. Quadriceps muscle oxygen saturation and total hemoglobin will be measured using a Moxy near-infrared spectroscopy monitor during the Incremental Shuttle Walk Test. Exercise capacity, dynamic balance, and agility will be assessed using the Incremental Shuttle Walk Test, Star Excursion Balance Test, and T-Test, respectively.

Eligibility

Sex
MALE
Min age
18 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Male, aged 18 to 25 years * Regular participation in volleyball training * University student actively playing on an elite-level volleyball team * Regular training during the previous 3 months * Willing and able to provide written informed consent Exclusion Criteria: * Current smoking or regular alcohol use * Regular use of medication or vitamin supplements * History of upper respiratory tract infection or COVID-19 within the previous 3 months * Lower-extremity or shoulder surgery within the previous 6 months * An acute respiratory or musculoskeletal condition that prevents safe completion of the protocol * Inability to complete the assessment or training procedures

Primary outcome measure(s)

  • Change in Quadriceps Total Hemoglobin During the Incremental Shuttle Walk Test — Baseline and immediately after the single-session intervention or control period, within the same day
    Total hemoglobin (THb, g/dL) will be recorded continuously using a Moxy near-infrared spectroscopy monitor positioned over the midpoint of the right quadriceps femoris. Mean THb will be summarized separately for the pre-exercise rest, exercise, and recovery phases of the Incremental Shuttle Walk Test. For each phase, change will be calculated as the post-intervention value minus the pre-intervention value. The primary comparison will be the difference in pre-to-post change between the intervention and control groups.
  • Change in Quadriceps Muscle Oxygen Saturation During the Incremental Shuttle Walk Test — Baseline and immediately after the single-session intervention or control period, within the same day
    Muscle oxygen saturation (SmO2, %) will be recorded continuously using a Moxy near-infrared spectroscopy monitor positioned over the midpoint of the right quadriceps femoris. Mean SmO2 will be summarized separately for the pre-exercise rest, exercise, and recovery phases of the Incremental Shuttle Walk Test. For each phase, change will be calculated as the post-intervention value minus the pre-intervention value. The primary comparison will be the difference in pre-to-post change between the intervention and control groups.

Trial sites (1)

FacilityCityRegionStatus
Gazi University Faculty of Health Sciences Department of Cardiopulmonary Physiotherapy and Rehabilitation, Ankara, Çankaya 06490 Ankara Ankara Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07763002 on ClinicalTrials.gov ↗ ← All trials in Turkey